Sign in

You're signed outSign in or to get full access.

Sylvan Tuerkcan

Senior Research Analyst at Citizens JMP Securities

Silvan Tuerkcan is a Senior Research Analyst at Citizens JMP Securities, specializing in biotechnology and medical sector equity research with a focus on small- and mid-cap pre-revenue companies targeting unmet needs. He covers companies such as CRISPR Therapeutics, Terns Pharmaceuticals, Nuvation Bio, Exelixis, and Intellia Therapeutics, achieving a strong performance track record including a 48% success rate and 19% average return per TipRanks, alongside a 42.5% success rate and 7.6% average return over the past year. Tuerkcan joined JMP Securities in January 2021 as a senior equity research analyst after serving as executive director and senior research analyst at UBS and Oppenheimer, with prior roles at Goldman Sachs and postdoctoral positions at Stanford and Institut Pasteur; he holds a PhD in biophysics from Ecole Polytechnique, an MSc in engineering physics from TU Munich, and a BSc in physics from McGill University.

Sylvan Tuerkcan's questions to Nuvation Bio (NUVB) leadership

Question · Q4 2025

Sylvan Tuerkcan from Citizens JMP Securities inquired about the stabilization of the gross-to-net for IBTROZI's pricing, its current level, and the expected long-term gross-to-net.

Answer

CFO Philippe Sauvage stated that the gross-to-net was 'a little bit above 25%' for Q4 and is expected to 'grow a little bit beyond that' before stabilizing. He noted that stabilization timing depends on payer negotiations but emphasized broad patient access as a priority. CEO David Hung confirmed that the gross-to-net will still increase slightly in coming quarters.

Ask follow-up questions

Fintool

Fintool can predict Nuvation Bio logo NUVB's earnings beat/miss a week before the call